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health state. They could remain in the same state or move to other states over time. The cycle length was 6 months. The structure of the model was illustrated.
Outcomes assessed in the review
The outcomes estimated from the literature were: the incidence rates for pneumococcal meningitis, bacteraemia, pneumonia, otitis media, and MVT; mortality rates; and vaccine efficacy rates.
Study designs and other criteria for inclusion in the review
A systematic review of the literature does not appear to have been conducted. The design of the primary studies was not reported in detail. Some of the data were derived from a clinical trial, the Northern California Kaiser Permanente Study.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Nine primary studies provided the effectiveness evidence.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
All the incidence rates were in children aged less than 10 years.
The mean annual incidence rate was 3 cases per 100,000 children for pneumococcal meningitis and 25 cases per 100,000 children for pneumococcal bacteraemia.
The incidence of pneumonia was 2,561.7 cases per year per 100,000 children.
The incidence of otitis media was 49,000 cases per year per 100,000 children.
The incidence of MVT was 1,585 cases per 100,000 children.
The mortality rate per 100 children was 6.6 for pneumococcal meningitis and 1.26 for bacteraemia.
Vaccine efficacy was 90%.
In particular, the use of the vaccine reduced the incidence of all-cause pneumonia by 11.4% and all-cause otitis media by 5.8%.
There was also a 10.6% reduction in recurrent acute otitis media, a 24.9% reduction in MVT procedures, and a 33% reduction in episodes of radiographically confirmed pneumonia.
Efficacy decreased by 3% per year for years 6 to 10 after initial vaccination.
Vaccine efficacy for infants aged less than 6 months was 33%.
Measure of benefits used in the economic analysis
The summary benefit measure was the number of life-years saved with vaccination over no vaccination. This was derived from the decision model. An annual discount rate of 3% was applied as the long-term benefits were estimated. Other relevant outputs of the model were the total number of cases of disease and deaths associated with the two strategies.
Direct costs
An annual discount rate of 3% was applied as the costs were incurred over a long timeframe. The unit costs were presented, while the quantities of resources used were derived from probabilities of events used in the model. The health services included in the economic evaluation were medical costs (physician visits, hospital stay, vaccine, diagnostic tests, antibiotic therapy) and non-medical costs (transportation). The cost/resource boundary of the health care system was adopted for the analysis of the direct costs. Resource use was estimated on the basis of patterns of care defined by a panel of experts and published evidence. The costs were derived from several sources, such as Ontario payment rates, a published study, and experts' opinions. All the costs were presented in 2000 values.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs (i.e. those associated with productivity losses) were included in the analysis since a societal perspective was adopted. The unit costs were presented separately from the quantities of resources used. The costs were estimated using the mean hourly wage for Ontario, as given by Statistics of Canada. Resource use was based on experts' assumptions. An annual discount rate of 3% was applied and the costs were presented in 2000 values.
Currency
Canadian dollars (Can$).
Sensitivity analysis
Multivariate sensitivity analyses were conducted to assess the robustness of the estimated cost-effectiveness ratios to variations in the model inputs. It was reported that the results were tabulated for 10,000 different combinations of possible values. The efficacy rates for each of the four diseases were varied simultaneously across their 95% confidence intervals. Incidence estimates were varied simultaneously within a range of +/-50% of the baseline values. Univariate sensitivity analyses were carried out on the incidence of meningitis using an alternative source of estimate. Finally, an analysis of the three catch-up populations was also conducted.
NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2019 University of York
Page: 3 / 6
Estimated benefits used in the economic analysis
In a birth cohort of 340,000 children for a 10-year time period, the total number of cases of disease would be: Therefore, the vaccination strategy led to a reduction of 99,887 cases of disease (609 bacteraemia, 74 meningitis, 8,187 pneumonia, 80,418 otitis media, and 10,599 MVT).
The number of deaths was 5 with vaccination and 17 without vaccination. Therefore, 12 cases were avoided with vaccination.
Assuming a life-expectancy of 78 years, there would be 938 undiscounted life-years gained (or 349 discounted lifeyears gained) with vaccination over no vaccination.
Cost results
The direct medical costs accounted for the highest proportion of the total costs.
The total disease costs (in millions) without vaccination were Can$898.5 (i.e. Can$483.8 for direct medical costs, Can$414.7 for indirect and direct non-medical costs, and Can$5.1 for future productivity costs).
The total disease costs (in millions) with vaccination were Can$835.5 (i.e. Can$447.2 for direct medical costs, Can$388.3 for indirect and direct non-medical costs, and Can$1.4 for future productivity costs).
Thus vaccination led to cost-savings of Can$63 (Can$36.6 for direct medical costs, Can$26.4 for indirect and direct non-medical costs, and Can$3.7 for future productivity costs).
The break-even cost of vaccination (including an administration fee and discounted fourth dose) was Can$50 from the societal perspective and Can$27 when only the direct costs relevant to the health care system were considered.
At the baseline vaccine cost of Can$67.50, the expected total costs (in million) from the societal perspective would be Can$903.5 without vaccination and Can$927.4 with vaccination. This resulted in an extra cost of Can$23.8 for the whole cohort with vaccination.
Synthesis of costs and benefits
Incremental cost-effectiveness ratios were calculated to combine the costs and benefits of vaccination versus no vaccination.
From a societal perspective, the incremental cost per life-year gained with vaccination over no vaccination (after excluding future productivity costs in order to avoid double-counting) was Can$29,287 when the health benefits were not discounted and Can$78,778 when the benefits were discounted.
From the health care payer perspective, the incremental cost per life-year gained was Can$154,591 after discounting the health benefits.
From the societal perspective, the incremental cost per illness avoided was Can$275 at a vaccine cost of Can$67.50.
The analysis of the three catch-up populations showed that the break-even cost of vaccination was:
Can$64 (societal) and Can$35 (payer) for children who received initial vaccination during the age of 7 to 11 months (catch-up 1: 3-dose schedule);
